Citations 32
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Denlinger, Crystal S. , Enzinger, Peter C. , Fanta, Paul T. , Farjah, Farhood , Gerdes, Hans, Glasgow, Robert E. , Hayman, James A. , Hochwald, Steven N. , Hofstetter, Wayne L. , Ilson, David H. , Jaroszewski, Dawn E. , Johung, Kimberly L. , Keswani, Rajesh N. , Kleinberg, Lawrence , Leong, Stephen , Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael J. , Mulcahy, Mary F. , Paluri, Ravi Kumar , Park, Haeseong , Poultsides, George A. , Roses, Robert E. , Strong, Vivian E. , Wiesner, Georgia L. , Willett, Christopher G. , Wright, Cameron D., McMillian, Nicole R., Pluchino, Lenora A. , Jaroszewski, Dawn, Ajani, Jaffer A , Bentrem, David J. , Chao, Joseph , Gibson, Michael K. , Perry, Kyle A. , Pimiento, José M.
Journal of the National Comprehensive Cancer Network | July 18, 2019 | Volume: 17 | Issue: 7 | Pages: 855-883
Abstract Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, Daniel G. , Thompson, John A. , Albertini, Mark R. , Barker, Christopher A. , Carson, William E. , Contreras, Carlo M. , DiMaio, Dominick J. , Fleming, Martin D. , Freeman, Morganna , Galan, Anjela , Gastman, Brian , Guild, Valerie, Johnson, Douglas B. , Lange, Julie R., Nath, Sameer K., Olszanski, Anthony J. , Ott, Patrick A. , Gupta, Aparna Priyanath , Ross, Merrick I. , Salama, April K.S. , Skitzki, Joseph J. , Sosman, Jeffrey A. , Wuthrick, Evan , McMillian, Nicole R., Engh, Anita M. , Carson, William E , Olszanski, Anthony J , Daniels, Gregory A. , Fields, Ryan C. , Joseph, Richard W. , Swetter, Susan M. , Tanabe, Kenneth K.
Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 367-402
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.